Norway Peptide Drug Conjugates Market Size & Outlook
Norway peptide drug conjugates market, 2018-2030 (US$M)
Related Markets
Norway peptide drug conjugates market highlights
- The Norway peptide drug conjugates market generated a revenue of USD 2.0 million in 2023 and is expected to reach USD 10.9 million by 2030.
- The Norway market is expected to grow at a CAGR of 27.5% from 2024 to 2030.
- In terms of segment, therapeutics was the largest revenue generating type in 2023.
- Therapeutics is the most lucrative type segment registering the fastest growth during the forecast period.
Peptide drug conjugates market data book summary
| Market revenue in 2023 | USD 2.0 million |
| Market revenue in 2030 | USD 10.9 million |
| Growth rate | 27.5% (CAGR from 2023 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Therapeutics |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Diagnostics |
| Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global peptide drug conjugates market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany peptide drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 123.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peptide Drug Conjugates Market Scope
Peptide Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway peptide drug conjugates market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 80% in 2023. Horizon Databook has segmented the Norway peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
Like other European countries, Norway witnesses a high demand for peptide-based drugs due to the high prevalence of target diseases in the country. Major causes of death in Norway are cancer and cardiovascular diseases.
According to Globocan 2020, the number of new cancer cases in Norway was 34,902, causing the death of around 11.2 thousand people. Moreover, the country shows a high prevalence of cardiovascular diseases, accounting for approximately 10.2 thousand deaths in 2021.
Furthermore, key players are focusing on developing newer formulations to meet the increasing demand for new-generation products in the market.
Reasons to subscribe to Norway peptide drug conjugates market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway peptide drug conjugates market databook
-
Our clientele includes a mix of peptide drug conjugates market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway peptide drug conjugates market , including forecasts for subscribers. This country databook contains high-level insights into Norway peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway peptide drug conjugates market size, by type, 2018-2030 (US$M)
Norway Peptide Drug Conjugates Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
